Aemetis, trading as (NASDAQ: AMTX), is carving a niche in the renewable natural gas and biofuels sector, with an emphasis on producing below-zero carbon intensity products. Founded in 2006 and headquartered in Cupertino, California, the company targets the replacement of traditional petroleum-based products through advanced biorefineries.
Aemetis operates a 60 million-gallon-per-year ethanol facility in California's Central Valley and a 50 million-gallon-per-year production site in India, supplying high-quality biodiesel and glycerin across India, the US, and Europe. The company's innovative edge is underpinned by a robust portfolio of patents, demonstrated by its R&D laboratory at the Maryland Biotech Center.
In its latest financial upturn, Aemetis secured a $100.00M Post-IPO Debt investment in November 2021 from Third Eye Capital. This investment highlights confidence in Aemetis's capacity to further its foothold in the ESG, Energy, and Renewable Energy industries.